Responses
Regular and young investigator award abstracts
Clinical trials in progress
357 TAK-573, an anti-CD38–attenuated interferon alpha (IFNα) fusion protein (Attenukine™), has demonstrated IFNα receptor (IFNAR) pathway modulation in patients with relapsed/refractory multiple myeloma
Compose a Response to This Article
Other responses
No responses have been published for this article.
